

## CLAIMS

- Sub A1
1. A pharmaceutical composition comprising:  
an effective amount of amlodipine;  
an effective amount of hydroxylated atorvastatin metabolite (ATM) ; and  
pharmaceutically acceptable formulation agents, the effect amounts of amlodipine and ATM  
coordinated to substantially inhibit lipid peroxidation in human low density lipoprotein or lipid  
membrane to achieve a therapeutic effect.
  2. The pharmaceutical composition of claim 1 wherein the amlodipine is provided as an  
effective derivative of amlodipine.
  3. The pharmaceutical composition of claim 2 wherein the therapeutically effective  
derivative of amlodipine comprises amlodipine besylate.
  - Sub A2  
4. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition  
reduces the risk of arterial and related heart disease.
  5. The pharmaceutical composition of claim 4 wherein said arterial and related heart disease  
is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis,  
arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke,  
and angina pectoris.
  - Sub A3  
6. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition  
lowers blood pressure.

Sub  
A3

7. The pharmaceutical composition of claim 6 wherein said pharmaceutical composition lowers blood pressure to a level consistent with a reduced risk of arterial and related heart disease.

8. The pharmaceutical composition of claim 6 wherein said pharmaceutical composition lowers blood pressure to a level statistically equivalent to normal.

9. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition lowers systemic lipid concentrations.

10. The pharmaceutical composition of claim 9 wherein said pharmaceutical composition lowers systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

11. The pharmaceutical composition of claim 9 wherein said pharmaceutical composition lowers systemic lipid concentrations to a level statistically equivalent to normal.

12. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations.

13. The pharmaceutical composition of claim 12 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

100344-10001  
T06T0T-0HTE00T

Sub  
#3  
AmX

14. The pharmaceutical composition of claim 12 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

15. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition concomitantly lowers blood pressure and systemic lipid concentrations.

16. The pharmaceutical composition of claim 15 wherein said pharmaceutical composition concomitantly lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

17. The pharmaceutical composition of claim 15 wherein said pharmaceutical composition concomitantly lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

18. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations.

19. The pharmaceutical composition of claim 18 wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

20. The pharmaceutical composition of claim 18 wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

21. The pharmaceutical composition of any of claims 15-17 and 18-20 wherein the concomitant lowering of blood pressure and systemic lipid concentrations results at least partially from reduced lipid oxidation.

22. A pharmaceutical composition comprising:

a therapeutically effective amount of a combination of amlodipine and — hydroxylated atorvastatin metabolite; and

pharmaceutically acceptable formulation agents wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations at least partially as a result of reduced lipid oxidation.

23. The pharmaceutical composition of claim 22 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

24. The pharmaceutical composition of claim 23 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

25. The pharmaceutical composition of claim 22 wherein said pharmaceutical composition reduces the risk of arterial and related heart disease.

26. The pharmaceutical composition of claim 25 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

SW  
A6

27. The pharmaceutical composition of claim 22 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

28. The pharmaceutical composition of claim 22 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

29. A method of treating arterial and related heart disease and substantially inhibit lipid peroxide in LDL and lipid membranes comprising administering a therapeutically effective amount of a combination of amlodipine and hydroxylated atorvastatin metabolite.

30. The method of claim 29 wherein amlodipine comprises an effective derivative of amlodipine.

31. The method of claim 30 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

32. The method of claim 29 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

33. The method of claim 29 wherein amlodipine and the atorvastatin metabolite are administered in the same therapeutic.

34. The method of claim 29 wherein amlodipine and the atorvastatin metabolite are administered as separate therapeutics.

35. The method of claim 29 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

36. The method of claim 29 wherein amlodipine and the atorvastatin metabolite are administered at different times.

37. A method of substantially inhibiting lipid oxidation and lowering blood pressure and systemic lipid concentrations comprising administering a therapeutically effective amount for such purposes of a combination of amlodipine and o-hydroxylated atorvastatin metabolite.

38. The method of claim 37 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

39. The method of claim 38 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

40. The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered in the same therapeutic.

41. The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered as separate therapeutics.

42. The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

43. The method of claim 37 wherein amlodipine and the atorvastatin metabolite are administered at different times.

44. The method of claim 37 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

45. The method of claim 37 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

46. The method of claim 37 wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

47. The method of any of claims 37-46 wherein the lowering of blood pressure and systemic lipid concentrations results at least partially from reduced lipid oxidation.

48. A method of synergistically inhibiting lipid oxidation comprising administering a therapeutically effective amount of a combination of amlodipine and hydroxylated atorvastatin metabolite.

49. The method of claim 48 wherein amlodipine comprises a therapeutically effective derivative of amlodipine.

50. The method of claim 49 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

51. The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered in the same therapeutic.

52. The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered as separate therapeutics.

53. The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered at the same time.

54. The method of claim 48 wherein amlodipine and the atorvastatin metabolite are administered at different times.

55. The method of claim 48 wherein said pharmaceutical composition inhibits lipid oxidation to an extent consistent with a reduced risk of arterial and related heart disease.

56. The method of claim 55 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

57. A pharmaceutical composition comprising:

a therapeutically effective amount of amlodipine;

a therapeutically effective amount of hydroxylated atorvastatin metabolite; and

pharmaceutically effective formulation agents.



58. The pharmaceutical composition of claim 57 where the amlodipine comprises a therapeutically effective derivative of amlodipine.

59. The pharmaceutical composition of claim 57 wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

60. A method of lowering blood pressure and systemic lipid concentrations comprising administering a therapeutically effective amount of combination of amlodipine and hydroxylated atorvastatin metabolite.

61. The method of claim 60 wherein said pharmaceutical composition synergistically lowers blood pressure and systemic lipid concentrations to a level statistically equivalent to normal.

62. The method of claim 61 wherein the synergistic lowering of blood pressure and systemic lipid concentrations results at least partially from reduced lipid oxidation.

add  
AS